Enliven Therapeutics (NASDAQ:ELVN) Director Sells $32,201.40 in Stock
Enliven Therapeutics Director Richard Heyman sold 1,230 shares of ELVN stock on February 17th for a total of $32,201.40, reducing his position by 5.15%. The company's stock currently trades around $26.16, with a market cap of $1.55 billion and significant institutional ownership at 95.08%. Analysts maintain a "Moderate Buy" rating with a target price of $41.00.
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Down 14.1% in January
Enliven Therapeutics (NASDAQ:ELVN) experienced a 14.1% decrease in short interest in January, with total short interest falling to 7,870,182 shares. This represents 17.9% of shares short and a days-to-cover ratio of 7.9 days based on average daily volume. The article also highlights significant insider selling, institutional holdings, analyst ratings (Moderate Buy with a $41 price target), and the company's financial performance.
(ELVN) Movement as an Input in Quant Signal Sets
This article from Stock Traders Daily discusses how movement serves as an input in quantitative signal sets for Enliven Therapeutics Inc. (NASDAQ: ELVN). It highlights conflicting sentiment across different time horizons, suggesting choppy conditions and elevated downside risk. The analysis provides AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide potential trades and manage risk.
Candriam S.C.A. Raises Stock Position in Enliven Therapeutics, Inc. $ELVN
Candriam S.C.A. significantly increased its stake in Enliven Therapeutics (NASDAQ:ELVN) by 46.3% in the third quarter, bringing its total holdings to 609,352 shares valued at approximately $12.47 million. Despite recent insider selling, which saw 257,613 shares sold, institutional investors now own 95.08% of the clinical-stage biotech company. Enliven Therapeutics, with a market capitalization of $1.66 billion, recently reported stronger-than-expected earnings and holds an average analyst rating of "Moderate Buy" with a target price of $41.00.
Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $145,200.00 in Stock
Enliven Therapeutics (NASDAQ:ELVN) Director Joseph Lyssikatos sold 5,000 shares of the company's stock on February 6th for $145,200.00, reducing his stake by 0.67%. The sale was reported in an SEC filing, and following the transaction, Lyssikatos directly owns 740,188 shares valued at approximately $21.5 million. Analysts currently rate ELVN stock as a "Moderate Buy" with an average price target of $41.00.
Lyssikatos, Enliven Therapeutics CSO, sells $145k in shares
Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics (NASDAQ:ELVN), sold 5,000 shares of company stock for approximately $145,219 on February 6, 2026. This sale was executed under a Rule 10b5-1 trading plan after ELVN shares surged over 81% year-to-date and are trading near their 52-week high, though Lyssikatos still retains a significant stake in the company. Enliven Therapeutics is advancing its oncology pipeline, including promising clinical trial results for its CML drug candidate ELVN-001 and upcoming Phase 3 trials, alongside recent leadership changes.
Lyssikatos, Enliven Therapeutics CSO, sells $145k in shares
Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold 5,000 shares of common stock for approximately $145,219 on February 6, 2026. This transaction occurred after ELVN shares surged over 81% year-to-date and was executed under a Rule 10b5-1 trading plan. Enliven Therapeutics recently announced promising Phase 1b clinical trial results for its CML drug candidate ELVN-001 and is preparing for Phase 3 trials and leadership changes.
Assessing Enliven Therapeutics (ELVN) Valuation After CSO Share Sale And Early Leukemia Trial Progress
Enliven Therapeutics (ELVN) is being re-evaluated after its CSO sold shares and positive early data emerged from its ELVN-001 leukemia trial. Despite strong recent share price momentum, the company remains loss-making, prompting questions about its current valuation. While its Price-to-Book ratio appears inexpensive compared to peers but premium to the broader industry, a Discounted Cash Flow model suggests the stock might be overvalued at its current price.
Enliven Therapeutics Executive Sells 20,000 Shares
Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, sold 20,000 shares for $535,100 on January 20, 2026, a sale significantly larger than his historical median. This transaction, coupled with a previous COO sale, raises potential investor concerns despite the company's stock surge after positive ELVN-001 leukemia treatment data and "strong buy" analyst ratings. The company is advancing ELVN-001 to phase three clinical trials, aiming for continued growth.
Enliven Therapeutics CFO sells $22,524 in stock
The article reports that Enliven Therapeutics' CFO sold $22,524 worth of company stock. This transaction indicates insider selling activity at the biotechnology firm.
Enliven Therapeutics CFO sells $22,524 in stock
This article reports that the CFO of Enliven Therapeutics sold $22,524 worth of company stock. This transaction details an insider selling activity.
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of "Moderate Buy" by Brokerages
Five analysts have issued a "Moderate Buy" consensus rating for Enliven Therapeutics (NASDAQ:ELVN), with an average one-year price target of $41.00. While insiders, including the CEO and a director, sold approximately $6.64 million worth of shares recently, they still retain a 25.90% ownership. The company's stock opened at $25.87, with earnings per share last quarter beating estimates by $0.11 at -$0.32.
Enliven Therapeutics director Heyman sells $32,901 in stock By Investing.com
Richard A. Heyman, a director at Enliven Therapeutics Inc. (NASDAQ:ELVN), sold 1,230 shares of company stock for a total of approximately $32,901 on January 20, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, Enliven Therapeutics recently announced positive Phase 1b data for its CML drug candidate ELVN-001, showing a 69% cumulative major molecular response rate by 24 weeks.
Enliven Therapeutics director Heyman sells $32,901 in stock By Investing.com
Richard A. Heyman, a director at Enliven Therapeutics Inc (NASDAQ:ELVN), sold 1,230 shares of company stock for approximately $32,901 on January 20, 2026. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan. The transactions leave Heyman with significant direct and indirect holdings in the company's common stock.
Joseph Lyssikatos Sells 20,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock
Joseph Lyssikatos, an insider at Enliven Therapeutics (NASDAQ:ELVN), sold 20,000 shares of the company's stock for $535,000 on January 20th, reducing his holding by 2.61%. Following the sale, Lyssikatos directly owns 745,188 shares, valued at approximately $19.93 million. Enliven Therapeutics is trading down 0.6%, with a market cap of $1.60 billion, and analysts maintain a "Moderate Buy" rating with an average target price of $41.00.
Enliven Therapeutics director Heyman sells $32,901 in stock
Richard A. Heyman, a director at Enliven Therapeutics Inc, sold 1,230 shares of the company's common stock for approximately $32,901 in two separate transactions on January 20, 2026. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, Enliven Therapeutics recently announced positive Phase 1b data for its CML drug candidate ELVN-001 and made leadership changes, including the appointment of a new CEO and a new board member.
Enliven Therapeutics director Heyman sells $32,901 in stock By Investing.com
Richard A. Heyman, a director at Enliven Therapeutics Inc (NASDAQ:ELVN), sold 1,230 shares of the company's common stock for approximately $32,901 on January 20, 2026. These sales were executed under a pre-arranged Rule 10b5-1 trading plan. The article also mentions recent positive Phase 1b data for ELVN-001, upcoming Phase 3 trials, and new leadership appointments at Enliven Therapeutics.
Enliven Therapeutics (NASDAQ:ELVN) Director Sells 1,230 Shares
Enliven Therapeutics Director Richard Heyman sold 1,230 shares of ELVN stock on January 20th for $32,902.50, reducing his stake by 4.90%. The company's stock trades at $27.03 with a market cap of $1.60 billion and a negative P/E ratio, while analysts rate it a "Moderate Buy" with a $41 consensus price target. Institutional investors hold a significant portion of the stock, with several major funds recently increasing their positions.
Stocks To Watch: Enliven Therapeutics Sees RS Rating Jump To 85
Enliven Therapeutics (ELVN) has achieved an impressive Relative Strength (RS) Rating of 85, placing it among stocks showing strong price performance. This rating, provided by Investor's Business Daily, helps identify stocks with significant market leadership. Investors are advised to look for stocks with an RS Rating of 80 or higher for their watch lists.
Assessing Enliven Therapeutics (ELVN) Valuation After Positive Phase 1b ENABLE Trial Update
Enliven Therapeutics (ELVN) stock has seen significant momentum after positive Phase 1b ENABLE trial data for its CML candidate, ELVN-001, showing clinical activity and a clean safety profile. While the price-to-book ratio suggests the stock is "about right" compared to peers, a DCF model indicates overvaluation at its current price of $26.71 against an estimated fair value of $17.99, prompting investors to consider if the premium is justified for an early-stage pipeline.
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 7.4% - Should You Buy?
Enliven Therapeutics (NASDAQ:ELVN) saw its stock price increase by 7.4% during mid-day trading on Friday, reaching $27.04. This surge occurred despite recent insider selling and a consensus "Moderate Buy" rating from analysts with a target price of $41.00. The company also beat its quarterly EPS estimates, reporting a $0.32 loss compared to an expected $0.43 loss.
Have Enliven Therapeutics Insiders Been Selling Stock?
An insider at Enliven Therapeutics recently sold US$348k worth of stock, which accounted for 7.4% of their total holding. While this sale was below the current stock price, suggesting potential insider sentiment about valuation, the overall insider ownership at 3.9% is not exceptionally high. The article notes the absence of insider share purchases over the past year and cautions investors due to these factors.
Have Enliven Therapeutics Insiders Been Selling Stock?
Enliven Therapeutics' Independent Chairman, Richard Heyman, recently sold US$348k worth of stock, reducing his holding by 7.4%. While this is the largest insider sale in the past year, insider ownership at 3.9% is not exceptionally high. The article suggests caution for investors due to no recent insider purchases and the presence of six warning signs for the company.
Anish Patel, COO of Enliven Therapeutics, sells $1.35m in ELVN
Anish Patel, COO of Enliven Therapeutics (NASDAQ: ELVN), sold 48,300 shares of the company's common stock for a total of $1,351,762. The sales were conducted on January 9, 2026, through a Rule 10b5-1 trading plan. This transaction leaves Patel indirectly holding 215,011 shares via a family trust, and comes amidst news of positive Phase 1b data for the company's CML drug candidate, ELVN-001, and upcoming Phase 3 trials.
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 41,302 Shares
Enliven Therapeutics (NASDAQ:ELVN) director Joseph Lyssikatos sold 41,302 shares of the company's stock on January 8th, totaling approximately $993,313. This transaction reduced his holdings by 4.6%. The stock's price slid 3.7% on the day, and analysts currently rate ELVN with a "Moderate Buy" consensus.
Enliven Therapeutics (NASDAQ:ELVN) Director Sells $241,164.05 in Stock
Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman sold 9,635 shares of the company's stock, totaling $241,164.05, on January 8th, reducing his stake by 27.39%. The transaction was disclosed in an SEC filing. The company currently has a "Moderate Buy" consensus rating from analysts with an average target price of $41.00.
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 8% - Here's What Happened
Enliven Therapeutics (NASDAQ:ELVN) saw its stock price drop 8% on Monday, trading down to $23.9150 with significantly reduced volume. Despite the dip, the company holds a "Moderate Buy" rating from analysts with an average price target of $41.00, and recently beat its earnings per share estimates. Insider selling has occurred, but institutional investors still hold a substantial portion of the company's stock.
Stocks with rising relative price strength: Enliven Therapeutics
This article identifies Enliven Therapeutics as a stock exhibiting rising relative price strength. This indicates that the stock is outperforming the broader market.
Experimental leukemia drug shows early promise for patients with few options
Enliven Therapeutics announced positive initial Phase 1b data for ELVN-001, its experimental drug for chronic myeloid leukemia (CML) in patients who are relapsed, refractory, or intolerant to existing therapies. The data showed encouraging cumulative major molecular response (MMR) rates and deep molecular response (DMR), alongside a favorable safety profile with no new safety signals. The company plans to align with the FDA on dosage for a Phase 3 trial initiation in the second half of 2026, with additional Phase 1 data expected mid-year.
Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging ENABLE Trial Data
Enliven Therapeutics (ELVN) shares have reacted positively to encouraging initial Phase 1b ENABLE data for ELVN-001 in chronic myeloid leukemia. Despite a short-term stock surge, the company's Price-to-Book ratio of 3.2x suggests it's overvalued compared to the broader US Pharmaceuticals industry, and a Discounted Cash Flow model places its fair value below the current share price, indicating potential risk. Investors are cautioned to consider both clinical and financing risks for this unprofitable, early-stage drug developer.
Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging ENABLE Trial Data
Enliven Therapeutics' (ELVN) shares saw a significant jump following positive Phase 1b ENABLE data for ELVN-001 in chronic myeloid leukemia patients. Despite short-term momentum and an average analyst target of $41.38, the article questions if the valuation at $26 is justified, especially given its 3.2x Price-to-Book ratio is above the US pharmaceutical industry average and a DCF model suggests a fair value of $17.99. The analysis highlights the need to consider clinical and financing risks for this unprofitable, early-stage biopharmaceutical company.
Enliven Therapeutics stock hits 52-week high at $25.64 By Investing.com
Enliven Therapeutics (ELVN) stock hit a 52-week high of $25.64, driven by a 49.61% weekly return and 50.97% year-to-date gain, reflecting strong investor confidence despite an InvestingPro analysis suggesting it may be overvalued. The company also reported positive Phase 1b data for its CML drug candidate ELVN-001 and announced leadership changes as it prepares for Phase 3 trials.
Enliven Therapeutics stock hits 52-week high at $25.64 By Investing.com
Enliven Therapeutics (ELVN) has reached a new 52-week high of $25.64, driven by strong investor confidence and positive market sentiment, with significant returns over the past week and year-to-date. The company, with a market capitalization of $1.51 billion and solid financial health, has also reported positive Phase 1b data for its chronic myeloid leukemia drug candidate, ELVN-001, and announced new leadership appointments. Despite an InvestingPro analysis suggesting the stock may be overvalued, analyst targets range from $33 to $52.
Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars
Enliven Therapeutics (NASDAQ: ELVN) stock surged after the company released promising initial data from its Phase 1b ENABLE trial for ELVN-001, a drug targeting chronic myeloid leukemia. The data showed favorable major molecular response and deep molecular response rates, comparable to approved treatments, with a good safety and tolerability profile. Enliven Therapeutics plans to begin its Phase 3 ENABLE-2 trial in the second half of 2026.
Enliven Therapeutics’ Initial Leukemia Drug Data Excite Investors, Shares Surge
Enliven Therapeutics Inc. (NASDAQ: ELVN) saw its shares surge by over 50% following the release of encouraging preliminary data from its Phase 1b ENABLE study for ELVN-001, a drug targeting chronic myeloid leukemia. The study showed promising major and deep molecular responses in patients resistant to current treatments, with a favorable safety profile across all tested doses. The company plans to advance ELVN-001 to a Phase 3 trial in the latter half of 2026.
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones
Enliven Therapeutics announced positive initial Phase 1b data for ELVN-001 in chronic myeloid leukemia (CML), demonstrating a 69% cumulative major molecular response rate by 24 weeks and a favorable safety profile. The company is preparing for regulatory interactions with the FDA and plans to initiate a Phase 3 trial in the second half of 2026. These results position ELVN-001 as a potential best-in-class treatment for CML, including against resistant mutations like T315I.
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones
Enliven Therapeutics announced positive initial Phase 1b data for ELVN-001 in chronic myeloid leukemia (CML), demonstrating a 69% cumulative major molecular response (MMR) rate by 24 weeks and a favorable safety profile. The data reinforces ELVN-001's potential as a best-in-class active-site TKI. The company plans regulatory alignment with the FDA and the initiation of a Phase 3 trial in the second half of 2026, targeting heavily pretreated CML patients who are relapsed, refractory, or intolerant to existing TKIs.
Enliven Therapeutics’ Initial Leukemia Drug Data Excite Investors, Shares Surge
Enliven Therapeutics Inc. (NASDAQ: ELVN) saw its shares surge by over 50% after releasing promising preliminary data from its Phase 1b ENABLE study for ELVN-001, a drug targeting chronic myeloid leukemia (CML). The clinical trial showed positive efficacy results, with a significant number of patients achieving major molecular response and deep molecular response, along with a strong safety and tolerability profile. The company plans to initiate a Phase 3 trial for ELVN-001 in the latter half of 2026.
Enliven Therapeutics stock hits 52-week high at $25.64
Enliven Therapeutics stock recently hit a new 52-week high of $25.64, driven by a 49.61% return over the past week and a 50.97% year-to-date increase. The company, with a market capitalization of $1.51 billion and strong financial health, also reported positive Phase 1b data for its CML drug candidate ELVN-001 and made changes to its leadership, with Rick Fair appointed as the new CEO.
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development
Enliven Therapeutics has appointed Scott Garland to its Board of Directors, a biopharma executive with extensive experience in oncology and hematology commercialization. This strategic move, coinciding with the departure of Andrew Phillips, Ph.D., prepares Enliven for the upcoming Phase 3 trial initiation for ELVN-001 in chronic myeloid leukemia and its subsequent commercialization. The company aims to align experienced leadership with its transition into late-stage development.
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of "Moderate Buy" from Brokerages
Enliven Therapeutics, Inc. (NASDAQ:ELVN) has received a consensus "Moderate Buy" rating from five brokerages, with an average 12-month price target of $41.00. Despite recent insider selling, institutional investors hold a significant majority of shares (95.08%), and the company recently surpassed quarterly EPS expectations. Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies for cancer.
Enliven Therapeutics CSO sells $84k in shares
Joseph P Lyssikatos, CSO of Enliven Therapeutics (NASDAQ:ELVN), sold 5,000 shares for approximately $84,206 on December 19, 2025, according to a pre-arranged trading plan. Despite this insider sale, analysts maintain a "Strong Buy" rating with significant upside potential, though InvestingPro indicates the stock is trading above its Fair Value. The company is preparing for a pivotal Phase 3 trial for its CML treatment and recently appointed a new CEO.
Enliven Therapeutics CSO sells $84k in shares By Investing.com
Enliven Therapeutics' Chief Scientific Officer Joseph P Lyssikatos sold 5,000 shares of common stock for approximately $84,206. Despite this insider selling, analysts maintain a "Strong Buy" consensus for the stock, with price targets suggesting significant upside potential. The company also recently appointed Rick Fair as its new CEO and is preparing for a pivotal Phase 3 trial for its CML treatment candidate, ELVN-001, in 2026.
Enliven Therapeutics CSO sells $84k in shares By Investing.com
Enliven Therapeutics' Chief Scientific Officer, Joseph P Lyssikatos, sold 5,000 shares for approximately $84,206 on December 19, 2025. Despite this insider selling, analysts maintain a "Strong Buy" consensus for the stock, with significant upside potential. Meanwhile, the company is preparing for a crucial Phase 3 trial for its CML treatment candidate, ELVN-001, in 2026, and recently appointed Rick Fair as its new CEO.
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 5,000 Shares of Stock
Joseph Lyssikatos, an insider at Enliven Therapeutics (NASDAQ:ELVN), sold 5,000 shares of the company's stock for $84,200. This transaction reduced his holdings by 0.55% to 897,688 shares. This sale comes as ELVN shares dropped approximately 7.8% on high volume.
Enliven Therapeutics CSO sells $84k in shares
Enliven Therapeutics (NASDAQ:ELVN)'s Chief Scientific Officer, Joseph P Lyssikatos, sold 5,000 shares of common stock for approximately $84,206 on December 19, 2025. This transaction, executed under a pre-arranged trading plan, comes as the clinical-stage oncology company prepares for a pivotal Phase 3 trial for its CML treatment candidate, ELVN-001. Despite the insider selling, analysts maintain a "Strong Buy" consensus, though the stock is currently trading above its Fair Value.
First Week of February 2026 Options Trading For Enliven Therapeutics (ELVN)
New options began trading this week for Enliven Therapeutics Inc (ELVN) with a February 2026 expiration. A call contract at the $17.50 strike price offers a potential 1.21% total return if the stock is called away, or a 0.58% premium boost (3.50% annualized) if it expires worthless. The implied volatility for this contract is 99%, compared to the trailing twelve-month actual volatility of 67%.
5AM Venture Management LLC Reduces Stock Holdings in Enliven Therapeutics, Inc. $ELVN
5AM Venture Management LLC significantly reduced its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN), selling 41.6% of its holdings, which amounted to 550,000 shares. Despite this reduction, Enliven Therapeutics remains 5AM Venture Management LLC's fourth-largest holding, representing approximately 6.0% of its total portfolio. Various other hedge funds adjusted their positions in the company, while insiders have also been selling shares.
Enliven Therapeutics Appoints Richard Fair as CEO
Enliven Therapeutics has appointed Richard Fair as its new President and CEO, succeeding co-founder Sam Kintz. This leadership change aligns with the company's strategy to advance its pivotal Phase 3 trial for ELVN-001 and enhance its market position. Despite a "Buy" rating from analysts with a $35.00 price target, Spark's AI Analyst rates ELVN as "Underperform" due to its early-stage financial profile, ongoing losses, and reliance on external financing.
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
Enliven Therapeutics (Nasdaq: ELVN) announced an inducement stock option grant to Richard Fair, its President and CEO, for 875,000 shares of common stock. This grant, with an exercise price of $18.77 per share, vests over time and was made as an inducement for Mr. Fair's employment, complying with Nasdaq Listing Rule 5635(c)(4). Enliven is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for precision oncology.
